Abstracts tagged "opportunistic infections and safety"

Abstract Number: 1515 • ACR/ARP Annual Meeting 2019
Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Marina Magrey¹, Victoria Navarro-Compán ², Sandra Garces ³, Xenofon Baraliakos ⁴, David Sandoval ³, Jeffrey Lisse ³, Silvia Santisteban ³, David Adams ³, Fangyi Zhao ³ and Robert Inman ⁵, ¹Division of Rheumatology, The MetroHealth System and School of Medicine, Case Western Reserve University, Cleveland, OH, ²University Hospital La Paz, IdiPaz, Madrid, Spain, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵University of Toronto, University Health Network, Toronto, ON, Canada
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets IL-17A. IL-17 inhibitors have shown efficacy for radiographic axial spondyloarthritis (r-axSpA), with IXE currently…